#### Accepted Manuscript

Optimization of Highly Selective 2,4-Diaminopyrimidine-5-carboxamide Inhibitors of Sky Kinase

Noel A. Powell, Jennifer K. Hoffman, Fred L. Ciske, Jeffrey T. Kohrt, Sangita M. Baxi, Yun-Wen Peng, Min Zhong, Cornel Catana, Jeff Ohren, Lisa A. Perrin, Jeremy J. Edmunds

PII:	S0960-894X(12)01612-5
DOI:	http://dx.doi.org/10.1016/j.bmcl.2012.12.028
Reference:	BMCL 19913

To appear in:

Bioorganic & Medicinal Chemistry Letters

Please cite this article as: Powell, N.A., Hoffman, J.K., Ciske, F.L., Kohrt, J.T., Baxi, S.M., Peng, Y-W., Zhong, M., Catana, C., Ohren, J., Perrin, L.A., Edmunds, J.J., Optimization of Highly Selective 2,4-Diaminopyrimidine-5-carboxamide Inhibitors of Sky Kinase, *Bioorganic & Medicinal Chemistry Letters* (2012), doi: http://dx.doi.org/10.1016/j.bmcl.2012.12.028

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



# Optimization of Highly Selective 2,4-Diaminopyrimidine-5carboxamide Inhibitors of Sky Kinase

# Noel A. Powell,<sup>\*</sup> Jennifer K. Hoffman,<sup>†</sup> Fred L. Ciske,<sup>‡</sup> Jeffrey T. Kohrt,<sup>§</sup> Sangita M. Baxi,<sup>\*\*</sup> Yun-Wen Peng, Min Zhong,<sup>§</sup> Cornel Catana, Jeff Ohren, Lisa A. Perrin, and Jeremy J. Edmunds,<sup>††</sup>

Pfizer Global Research & Development, Michigan Laboratories, Ann Arbor, MI 48105

This is where the receipt/accepted dates will go; Received Month XX, 2000; Accepted Month XX, 2000 [BMCL RECEIPT]

Abstract—Optimization of the ADME properties of a series of 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase resulted in the identification of highly selective compounds with properties suitable for use as in vitro and in vivo tools to probe the effects of Sky inhibition. ©2000 Elsevier Science Ltd. All rights reserved.

In the preceding paper, we reported the discovery and initial SAR of a series of 2,4-diaminopyrimidine-5-Sky is a carboxamide inhibitors of Sky kinase. tyrosine kinase receptor for the Gas6 (growth arrest specific gene 6) ligand, which plays a critical role as a amplifier, enhancing platelet platelet response aggregration and granule secretion to known endogenous agonists.<sup>2,3</sup> Previous studies from our laboratories have demonstrated that Sky specific antibodies inhibit human platelet degranulation and aggregation to the same extent as Gas6 inhibition, and result in comparable efficacy to clopidogrel treatment in a mouse model of thrombosis with no significant increase in bleeding time.<sup>4</sup> Therefore, Sky inhibitors are of interest as an arterial anti-thrombosis treatment

with a reduced risk of bleeding side affects.

Our initial structure-activity relationship (SAR) studies in the 2,4-diaminopyrimidine-5-carboxamide series demonstrated that high kinase selectivity could be achieved by filling the Ala571 subpocket with a benzylamino substituent at the 2-position of the pyrimidine core. However, early compounds suffered from high clearance and poor oral bioavailability due to rapid first pass metabolism. We undertook further SAR studies to improve the metabolic stability of the 2,4diaminopyrimidine-5-carboxamide template.

Amide sidechain analogs were prepared as described in Scheme 1. Condensation of **1** with cyclopentyl amine

<sup>§</sup> Current address: Pfizer Worldwide Research & Development, Eastern Point Road, Groton, CT 06442, USA

<sup>&</sup>lt;sup>\*</sup> Corresponding author at present address: Eisai Inc, 4 Corporate Drive, Andover, MA 01810, USA. Tel: +1 978 837 4683; email: noel\_powell@eisai.com

<sup>&</sup>lt;sup>†</sup> Current address: Hamilton Company, 4970 Energy Way, Reno, NV 89502

<sup>&</sup>lt;sup>\*</sup> Current address: Cayman Chemical, 1180 East Ellsworth Road, Ann Arbor, MI 48108

<sup>&</sup>lt;sup>\*\*</sup> Current address: Pfizer Worldwide Research & Development, 10646 Science Center Drive, San Diego, CA 92121, USA

<sup>&</sup>lt;sup>11</sup> Current address: Abbott Labs, 381 Plantation Street, Worcester, MA 01605, USA

the 4-(cyclopenthylamino)-pyrimidine afforded 2. Oxidation of the thiomethyl and displacement of the resulting sulfone with 2,5-dichlorobenzylamine provided the 2,4-diaminopyrimidine 3. Hydrolysis of the ester and amide bond formation yielded the desired analogs 4-14. Analogs with a 3,5-dichloroanilino substituent at the pyrimidine 2-position were prepared as described in Scheme 2. Condensation of 25 with neat 2,5-dichloroaniline provided the 2-aminopyrimidinone  $26^{5}$ , which was converted to the chloride by refluxing in thionyl chloride. The chloride was then displaced with a primary amine to give the 2,4-diaminopyrimidine



Table 1. Amide sidechain SAR and ADME properties

Scheme 1. a) cyclopentylamine,  $Et_3N$ ,  $CH_3CN$ , 80 °C; b) *m*-CPBA,  $CH_2Cl_2$ , 0 °C; c) 2,5-dichlorobenzylamine,  $Et_3N$ , 1,4-dioxane, reflux; d) NaOH, MeOH, reflux; e) RNH<sub>2</sub>, HATU,  $Et_3N$ , DMF.



**Scheme 2.** a) 3,5-dichloroaniline, neat, 150 °C; b) SOCl<sub>2</sub>, reflux; c) R-NH<sub>2</sub>, Et<sub>3</sub>N, CH<sub>3</sub>CN, reflux; d) NaOH, MeOH, reflux; e) *N*-Methyl-4-aminopiperidine, HATU, Et<sub>3</sub>N, DMF.



ID	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup> -NH	Sky IC <sub>50</sub> (μΜ) <sup>a</sup>	P-Selectin IC <sub>50</sub> (µM)	Platelet Aggregation IC <sub>50</sub> (μM)	cLogP	PSA	HLM t <sub>1/2</sub> (min)	RLM t <sub>1/2</sub> (min)	Solubility (µM) <sup>b</sup>	Permeability <sup>c</sup> (×10 <sup>-6</sup> cm/sec)	Dofetilide Binding %I @ 10 µM
4	OMe	н		0.40	17	46	4.34	108	14	16	81.6	1.5	7
5	CI	CI		0.36	3.1	28	5.85	99.3	6	4	3.9	0.1	23
6	CI	CI		0.070	7.4	29	6.06	108	2	<5	1.3	0	33
7	OMe	н	HN,OH	0.16	10	46	3.96	108	11	NT	7.8	0.9	35
8	OMe	Н		0.38	6.6	NT	3.61	117	5	NT	7.8	1.9	35
9	OMe	н		1.3	NT	NT	3.46	143	60	22	12	21	79
10	OMe	н		0.50	7.1	24	4.58	91	40	NT	200	NT	28
11	OMe	н	HN-N-	0.52	1.5	8.8	4.09	91	34	56	80	1.2	27
12	CI	CI	HN-N-	0.27	1.2	7.2	5.77	82	14	60	7.8	0.02	47

 $^{a}$  IC<sub>50</sub> data is an average of duplicate runs using an ELISA kinase assay with 60  $\mu$ M ATP.  $^{b}$  Aqueous solubility measured at pH 6.5.  $^{c}$  PAMPA artificial membrane assay.

ester 27. Hydrolysis of the ester and subsequent amide bond formation with the *N*-methyl-4-aminopiperidine yielded analogs 15-19.

As previously reported, both the 2-methoxybenzyl analog 4 and the 2,5-dichlorobenzyl analog 5 exhibited rapid HLM and RLM metabolism (Table  $1).^{1}$ The electron-rich benzyl ring of analog 4 appeared to be a likely site of metabolism upon visual inspection. However, replacing the methoxy ether with electron-withdrawing halogen atoms had no affect on the metabolic stability, indicating that the primary site of metabolism was elsewhere in the molecule. Metabolite identification by LC-MS-MS methods after incubation in human microsomes indicated the primary metabolite was actually the product of oxidative hydroxylation at the  $\alpha$ -carbonyl carbon in the butyrolactam ring. Our attempts to directly block that site of metabolism by replacement of the methylene with an oxygen atom resulted in 6with significant improvement in Sky inhibition potency, however, no improvement in HLM or RLM

We hypothesized that stability was observed. although the primary site of metabolism was blocked, alternative sites of metabolism on the highly lipophilic compound (cLogP = 6.06) now became dominant. Since the butyrolactam ring is exposed to the solvent face,<sup>1</sup> the affect of other polar solubilizing groups in the amide sidechain on the microsomal stability was examined. To keep the cLogP low, we opted to conduct the amide sidechain SAR with the 2methoxybenzyl group at the 2-position of the pyrimidine ring. Replacing the butyrolactam ring with a hydroxyl group (7) resulted in improved Sky inhibition activity, but had no affect on HLM stability and reduced aqueous solubility and cellular permeability. Likewise, a pendant acetamide (8) gave no improvement in HLM stability. A dramatic improvement in HLM stability was observed in the introduction of an acidic tetrazole (9, HLM  $t_{1/2} = 60$ min), along with a modest increase in the RLM halflife and improved aqueous solubility and permeability. However, the presence of the acidic tetrazole in the amide sidechain led to a 3-fold decrease in Sky

and, activity inhibition counter-intuitively, significantly increased dofetilide binding activity. We found that improved HLM stability could also be obtained by the introduction of basic amines in the amide sidechain. A N,N-dimethyl-4-aminobutyl chain exhibited similar Sky inhibition activity (10,  $IC_{50}$  = 0.50 µM), a 2.9-fold increase in HLM stability (HLM  $t_{1/2} = 40$  min), and excellent aqueous solubility. A (1methylpiperidin-4-yl)amino sidechain also exhibited similar Sky inhibition activity (11,  $IC_{50} = 0.52 \mu M$ ), good aqueous solubility a 2-fold increase in HLM stability ( $t_{1/2} = 40$  min), and improved metabolic stability in rat liver microsomes (RLM  $t_{1/2} = 56$  min). As observed previously, replacement of the 2methoxybenzyl group with the 2,5-dichlorobenzyl group resulted in decreased HLM stability (12, HLM  $t_{1/2} = 14$  min) and decreased solubility and permeability, presumably due to the increased lipophilicity of the 2,5-dichlorobenzyl group (cLogP = 5.77). However, analog 12 exhibited excellent RLM stability. The increased RLM stability of **11** and **12** translated into 41% and 32% oral bioavailability in the rat, respectively (Table 3). While the *in vivo* clearance for analogs 11 and 12 remained at or above the hepatic blood flow for the rat, we believe that the increased volume of distribution reflects an increase in protein binding that reduces the plasma free fraction. In any event, the resulting improved oral bioavailability of analogs 11 and 12 represents a significant improvement over earlier analogs.<sup>1</sup>

In addition to the improved oral bioavailability in the rat, analogs 11 and 12, which contain the *N*-methyl-4-aminopiperidine amide sidechain, also exhibit superior functional activity in both the functional P-selectin and platelet aggregation assays versus the corresponding analogs 4 and 5 with the *N*-(3-aminopropyl)-butyrolactam amide sidechain. The P-selectin assay measures the expression of P-selectin on the surface of platelets as a biomarker for platelet activation.<sup>6</sup>

While the improved RLM stability directly translated into improved oral bioavailability in the rat, we focused upon improving the HLM stability to ensure future druggability. Our attempts to improve the HLM stability by blocking metabolism of the amide sidechain appeared to be stymied by the overall lipophilicity of the compounds. We turned to decreasing the lipophilicity by introducing polar substituents into the 4-amino group which binds in the ribose region of the ATP binding site (Table 3), a strategy also recently demonstrated for other members of the HGFR kinase family.<sup>7</sup> We found that introduction of a basic amine into the 4-amino cvclic ring led to improved Sky inhibition activity (13 and 14, Sky IC<sub>50</sub> = 0.19 and 0.04  $\mu$ M, respectively), as well as improved HLM stability ( $t_{1/2} = 38$  and 23 min, respectively). Although the additional basic amine

resulted in good aqueous solubility, cellular permeability was drastically reduced. Indeed, analog 13 exhibited no oral bioavailability in the rat (Table 2), presumably due to the poor absorption across the gut wall. Therefore, we sought to further improve the metabolic stability and increase cellular permeability of the series. We recognized that the benzylic methylene in the 2-amino group represented a potential site of metabolism. We found that the 2aminobenzyl group could be replaced by a 2-anilino group, specifically a 3,5-dichloroanilino group, which exhibited single-digit nanomolar Sky inhibition activity and excellent HLM and RLM stability (15, Sky IC<sub>50</sub> = 0.002  $\mu$ M, HLM t<sub>1/2</sub> = 120 min, RLM t<sub>1/2</sub> = 60 min). However, the trans-2,4-diaminocyclohexane ring again resulted in poor permeability. Accordingly, we sought to replace the basic amine in the ribose binding region with neutral polar groups. Replacing the trans-2,4-diaminocyclohexane ring with a 4aminotetrahydropyran gave similar Sky inhibition potency (16, Sky  $IC_{50} = 0.002 \ \mu M$ ) and moderate HLM stability, but poor permeability. A cyclic amide sidechain also exhibited potent Sky inhibition and good HLM stability, but poor cellular permeability (17, Sky IC<sub>50</sub> =  $0.002 \mu$ M, PAMPA permeability = 0.2X 10<sup>-6</sup> cm/sec) In contrast, alcohol-containing sidechains resulted in potent Sky inhibition and good **HLM** stability with a relative increase in permeability (18 and 19, PAMPA permeability = 2.0 and  $1.4 \times 10^{-6}$ cm/sec, respectively). Analog 19 also exhibited good aqueous solubility and was chosen for PK dosing. Unfortunately, analog 19 exhibited increased in vivo clearance and no detectable plasma levels after oral dosing in the rat (Table 2). Although we were successful in improving the Sky inhibition activity, metabolic stability in HLM and RLM, and aqueous solubility via incorporation of polar functionality in the 3-amino sidechain that binds in the ribose binding region, these polar functionalities result in poor cellular permeability that severely limits the oral bioavailability.

The >100-fold improvement in Sky inhibition that was achieved by the incorporation of polar functionalities into the 4-amino sidechain did not translate into significantly improved activity in the platelet activation functional assays (Table 3). Analog **15** exhibited submicromolar activity in the P-selectin inhibition assay (IC<sub>50</sub> = 0.40  $\mu$ M) and single digit micromolar activity in the platelet aggregation assay (IC<sub>50</sub> = 1.4  $\mu$ M). While analogs **16** and **19** showed P-

Table 2. In vivo rat PK profile of selected compounds.<sup>a</sup>

I dole II											
Analog	t <sub>1/2</sub>	Cl	Cl Vdss		Cmax	F					
	(hr)	(mL/min/kg)	(L/kg)	(ng·hr/mL)	(ng/mL)	(%)					
11	3.5	73	18	302	74	41					
12	8	40	25	680	35	32					
13	0.2	40	0.4	0	25	0					
19	13	55	2.7	0	0	0					

<sup>a</sup>Values are means of duplicate experiments. Sprague-Dawley rats were

dosed as a suspension in 5% PEG-200/95% (0.5% w:w) methyl-

cellulose. IV dose = 1 mg/kg, PO dose = 5 mg/kg

Table 3. 2-Benzylamino and 2-Anilino SAR and ADME properties



ID	R <sup>1</sup> -NH	R <sup>2</sup> -NH	Sky IC <sub>50</sub> (μΜ) <sup>a</sup>	P-Selectin IC <sub>50</sub> (μM)	Platelet Aggregation IC <sub>50</sub> (μM)	clogP	PSA	HLM t <sub>1/2</sub> (min)	RLM t <sub>1/2</sub> (min)	Aqueous Solubility (μΜ) <sup>b</sup>	Permeability <sup>c</sup> (×10 <sup>-6</sup> cm/sec)	Dofetilide Binding Ki (µM)
13		HN-NH	0.19	>80	8.5	3.91	94	38	60	200	<0.1	>50
14		HN	0.041	1.1	NT	5.02	85	23	57	89	2.0	1.6
15		HN	0.002	0.40	1.4	5 <u>.</u> 57	85	120	60	200	0.3	6.7
16	HN CI	HN-O	0.009	1.2	NT	4.48	91	35	NT	40	<0.1	NT
17			0.006	0.43	NT	4.81	111	41	NT	2.3	0.2	4.0
18			0.003	0.58	NT	4.75	102	37	NT	3.5	2.0	3.4
19	HNCC	HN	0.010	2.2	9.6	4.07	112	74	60	40	1.4	0.98

 $^{a}$  IC<sub>50</sub> data is an average of duplicate runs using an ELISA kinase assay with 60  $\mu$ M ATP.  $^{b}$  Aqueous solubility measured at pH 6.5.  $^{c}$  PAMPA artificial membrane assay.

Table 4. Amide replacement SAR and ADME properties



ID	Het	R <sup>2</sup> -NH	Sky IC <sub>50</sub> (μM) <sup>a</sup>	P-Selectin IC <sub>50</sub> (μΜ)	clogP	PSA	HLM t <sub>1/2</sub> (min)	RLM t <sub>1/2</sub> (min)	Aqueous Solubility (μM) <sup>b</sup>	Permeability <sup>c</sup> (×10 <sup>-6</sup> cm/sec)	Dofetilide Binding Ki (µM)	СҮР2D6 %I @ 3 µМ
20	*N	HN-NH	0.092	1.6	4.92	87.9	21	3	5.2	0.2	1.3	81
21	*N	HN	0.0007	1.0	6.04	79.1	28	6	2.3	0.03	0.35	69
22	*/N	HN	0.044	3.0	4.52	92.2	120	31	200	1.0	1.5	88
23	*F		0.15	>80	6.03	79.3	48	60	200	<0.01	2.7	24
24	Br	HN	0.015	3.9	4.88	79.3	30	31	5.2	0.3	>100	1

 $IC_{50}$  data is an average of duplicate runs using an ELISA kinase assay with 60  $\mu$ M ATP. <sup>b</sup>Aqueous solubility measured at pH 6.5. <sup>c</sup> PAMPA artificial membrane assay.

selectin inhibition activity comparable to analogs 11 and 12, analogs 17 and 18 exhibited the most potent activity in the P-selectin assay in this series (P-selectin  $IC_{50} = 0.43$  and 0.58  $\mu$ M, respectively). Analog 15 may show superior functional activity because of better cellular permeability than is predicted by the PAMPA artificial membrane permeability assay.

We hypothesized that reducing the polar surface area and the number of basic amines and potential hydrogen bond donors by replacing the amide sidechain with a small heterocyclic ring or neutral atom would lead to improved cellular permeability and subsequently improved functional activity and oral bioavailability, (Table 4). On the basis of SAR data from another series identified in our HTS (data not shown), we chose to replace the amide sidechain with a 3-methylisoxazole while maintaining the basic amine in the ribose binding region. Analogs 20 and **21** exhibited potent Sky inhibition (Sky  $IC_{50} = 0.092$ and 0.0007 µM, respectively) and good functional activity in the P-selectin assay (IC<sub>50</sub> = 1.6 and 1.0  $\mu$ M, respectively). Although the PAMPA permeability data predicts that the more potent 21 would possess poor cellular permeability, the decreased polar surface area of **21** did result in improved functional activity. However, both analogs 20 and 21 exhibited reduced HLM and RLM stability, as well as significant dofetilide binding and CYP2D6 inhibition. To remove the dofetilide binding and CYP2D6 inhibition and improve the cellular permeability, we replaced the basic amine in the ribose binding region with the 3-

amino-4-hydroxy-tetrahydrofuran moiety of 19. We found that a 3-pyridyl ring was a good replacement for the amide sidechain, as analog 22 showed good Sky inhibition potency (Sky  $IC_{50} = 0.044 \ \mu M$ ) with improved HLM and RLM stability, aqueous solubility, and PAMPA permeability. However, 22 was still a potent inhibitor of CYP2D6 and showed no improvement in dofetilide binding inhibition. Conversion of the 3-pyridyl ring to a 4-fluorophenyl ring resulted in decreased CYP2D6 and dofetilide binding inhibition, but also resulted in a significant decrease in the Sky inhibition activity (23, Sky  $IC_{50}$  = 0.15 µM). We found that the most successful replacement of the amide sidechain was a simple bromine atom, which resulted in potent Sky inhibition (24, Sky IC<sub>50</sub> = 0.015  $\mu$ M), moderate functional Pselectin inhibition, good HLM and RLM stability, and no significant inhibition of CYP2D6 and dofetilide binding. However, the low aqueous solubility and PAMPA permeability was still not predictive of good oral bioavailability.

The broad kinase selectivity that we had previously observed for this series<sup>1</sup> was improved as the level of Sky inhibition activity increased throughout our SAR investigations (Table 5). Analogs **11** and **12**, with the *N*-(4-aminopiperidine) amide sidechain and 2-aminobenzyl group, exhibited improved selectivity against 32 kinases with significant activity in HGFR, Axl, and Mer, which are other members of the HGFR subfamily of kinases. The 2,5-dichlorobenzyl group in **12** resulted in additional activity in Abl, CKI- $\delta$ , and

Lck. Conversion of the 2,5-dichlorobenzyl group to the 3,5-dichloroanilino group and addition of a basic amine in the ribose binding region resulted in greatly improved kinase selectivity, as analog **15** exhibited >100 fold selectivity against 47/48 kinases screened, with activity only against the fellow HGFR kinase family member, Mer. Replacement of the basic amine in the ribose binding region with the non-basic 3amino-4-hydroxy-tetrahydrofuran ring in analog **19** resulted in >100 fold selectivity against all 48 kinases screened. In addition, replacement of the entire amide sidechain with a 3-methylisoxazole exhibited excellent selectivity in 46/48 kinases with some activity in MAP4K4 and Mer (analog **21**).

Table 5. Heatmap of kinase selectivity for selected compounds.<sup>a</sup>



<sup>a</sup> Fold selectivity (kinase IC<sub>50</sub>/Sky IC<sub>50</sub>) colored by green = >100 fold, yellow = 10-100 fold, red = <10 fold. IC<sub>50</sub> data for individual kinases can be found in the Supplementary Information available on-line.

In summary, we found that improved rat liver microsome (RLM) stability in a series of 2,4diaminopyrimidine-5-carboxamide inhibitors of Sky kinase could be achieved by modification of the amide sidechain. This effort resulted in analogs **11** and **12**, which exhibited good RLM stability and good oral bioavailability in the rat. To aid in future druggability, we were able to improve HLM stability by replacing the 2-benzylamino substituent with a 2-anilino group. Sky inhibition could also be improved by the addition of polar basic and non-basic functionalities in the 4amino group that binds in the ribose binding region, although this resulted in reduced cellular permeability. The amide sidechain could be replaced with small heterocyclic rings or a non-basic bromine atom while maintaining potent Sky inhibition and functional Pselectin activity. Analog **24** exhibited the best profile of Sky inhibition, functional activity, metabolic stability, and inhibition of CYP2D6 and dofetilide binding, although the aqueous solubility and cellular permeability are not predictive of good oral bioavailability. We believe that these results will aid in the future design of Sky inhibitors with improved drug-like properties, and that analogs **11** and **12** represent suitable tool compounds for use in in vitro and in vivo studies to probe the effects of Sky inhibition.

#### References

1. Powell, N. A.; Hoffman, J.; Ciske, F. L.; Kohrt, J. T.; Kaufman, M.; Quin, J.; Sheehan, D.; Edmunds, J. J.; Delaney, A.; Baxi, S.; Peng, Y.-W.; Bourbonaise, F.; Lee, D.-Y.; Schwende, F.; Chen, H.; Catana, C.; Ohren, J.; Perrin, L. A. *Bioorg. Med. Chem. Lett.* Submitted.

2. Saller, F.; Burnier, L.; Schapira, M.; Angelillo-Scherrer, A. *Blood Cells, Molecules, and Diseases* **2006**, *36*, 373-378.

3. Angelillo-Scherrer, A.; de Frutos, P. G.; Aparicio, C.; Melis, E.; Savi, P.; Lupu, F.; Arnout, J.; Dewerchin, M.; Hoylaerts, M. F.; Herbert, J.-M.; Collen, D.; Dahlbäck, B.; Carmeliet, P. *Nature Med.* **2001**, *7*, 215-221.

4. Gould, W. R.; Baxi, S. M.; Schroeder, R.; Peng, Y. W.; Leadley, R. J.; Peterson, J. T.; Perrin, L. A. *J. Thromb. Haemost.* **2005**, *3*, 733-741.

5. Ozeki, K.; Ichikawa, T.; Takehara, H.; Tanimura, K.; Sato, M.; Yaginuma, H. *Chem. Pharm. Bull.* **1989**, *37*, 1780-1787.

6. a) Shattil, S. J.; Cunningham, M.; Hoxie, J. A. *Blood* **1987**, *70*, 307-315. b) Sbrana, S.; Della Pina, F.; Rizza, A.; Buffa, M.; De Filippis, R.; Gianetti, J.; Clerico, A. *Cytomet Part B: Clin Cytomet* **2008**, *74B*, 30-39.

7. Liu, J.; Yang, C.; Simpson, C.; DeRyckere, D.; Van Deusen, A.; Miley, M. J.; Kireeve, D.; Norris-Drouin, J.; Sather, S.; Hunter, D.; Korboukh, V. K.; Patel, H. S.; Janzen, W. P.; Machius, M.; Johnson, G. L.; Earp, H. S.; Graham, D. K.; Frye, S. V.; Wang, X. ACS Med Chem Letters, **2012**, *3*, 129-134.

#### Highly Selective 2,4-Diaminopyrimidine-5carboxamide Inhibitors of Sky Kinase

Noel A. Powell, Jennifer K. Hoffman, Fred L. Ciske, Jeffrey T. Kohrt, Sangita M. Baxi, Yun-Wen Peng, Min Zhong, Cornel Catana, Jeff Ohren, Lisa A. Perrin, and Jeremy J. Edmunds

#### Pfizer Global Research & Development, Michigan Laboratories, Ann Arbor, MI 48105 USA

Optimization of the ADME properties of a series of 2,4diaminopyrimidine-5-carboxamide inhibitors of Sky kinase resulted in the identification of highly selective compounds with properties suitable for use as in vitro and in vivo tools to probe the effects of Sky inhibition.

